Monalizumab (IPH2201), a first-in class blocking mAb to NKG2A, is currently being tested in several phase I/II clinical trials for the safety and antitumor activity in various cancers, including chronic lymphocytic leukemia [123], squamous cell carcinoma of the head and neck (SCCHN), gynecologic cancers and advanced colorectal cancers (Table 19,10,11,12) [124]. This evidence concerns the gene KLRC1 and head and neck squamous cell carcinoma.